The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.
I farmaci biologici nelle malattie infiammatorie croniche intestinali / L. Spina, L. Pastorelli, G. De Nucci, F. Cavallaro, G.E. Tontini, N. Munizio, M. Vecchi. - In: GIORNALE ITALIANO DI ENDOSCOPIA DIGESTIVA. - ISSN 0394-0225. - 36:3(2013), pp. 179-183.
I farmaci biologici nelle malattie infiammatorie croniche intestinali
L. Pastorelli;G.E. Tontini;M. Vecchi
2013
Abstract
The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
